论文部分内容阅读
目的:观察匹多莫德防治脑性瘫痪(简称脑瘫)患儿反复呼吸道感染(RRI)的临床疗效及安全性。方法:将72例脑瘫合并RRI患儿随机分成观察组37例和对照组35例。两组患儿同时进行康复治疗,观察组加服匹多莫德每次400 mg,每天1次,持续服用60 d。观察两组患儿的临床症状,血清免疫球蛋白Ig A、Ig G、Ig M水平,肝肾功能,外周血象变化及不良反应。结果:治疗后,观察组Ig A、Ig G水平比治疗前升高(P<0.05),但Ig M与治疗前比较差异无统计学意义(P>0.05);对照组Ig A、Ig G、Ig M水平与治疗前比较差异均无统计学意义(P均>0.05)。与对照组比较,观察组呼吸道感染次数减少,发热时间、抗生素使用时间、咳嗽时间均缩短(P<0.05)。两组患儿治疗后BUN水平、ALT水平、WBC计数与治疗前比较差异均无统计学意义(P>0.05)。两组患儿不良反应发生率比较差异无统计学意义(P>0.05)。结论:匹多莫德用于防治脑瘫患儿RRI安全有效,值得临床推广应用。
Objective: To observe the clinical efficacy and safety of pidotimod in the prevention and treatment of recurrent respiratory tract infections (RRI) in children with cerebral palsy (CP). Methods: 72 children with cerebral palsy and RRI were randomly divided into observation group (37 cases) and control group (35 cases). Two groups of children with rehabilitation treatment at the same time, the observation group plus Pidmodomide 400 mg once daily for 60 days. Clinical symptoms, serum immunoglobulin Ig A, Ig G, Ig M levels, liver and kidney function, peripheral blood changes and adverse reactions were observed in both groups. Results: After treatment, the levels of Ig A and Ig G in the observation group were significantly higher than those before treatment (P <0.05), but there was no significant difference between the two groups (P> 0.05) There was no significant difference in IgM level between the two groups (P> 0.05). Compared with the control group, the observation group decreased the number of respiratory infections, fever time, antibiotic use time, cough time were shortened (P <0.05). There was no significant difference in BUN, ALT and WBC between the two groups after treatment (P> 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusion: Pidotimod is safe and effective for prevention and treatment of RRI in children with cerebral palsy and is worthy of clinical application.